Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
Aufreinigung
This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis
Immunogen
This FACL6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 240-270 amino acids from the Central region of human FACL6.
ACSL6
Reaktivität: Human
ELISA
Wirt: Kaninchen
Polyclonal
HRP
Applikationshinweise
For WB starting dilution is: 1:1000
For IHC-P starting dilution is: 1:50~100
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
2 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C,-20 °C
Informationen zur Lagerung
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
ACSL6
(Acyl-CoA Synthetase Long-Chain Family Member 6 (ACSL6))
FACL6 is involved in activation of long-chain fatty acids for both synthesis of cellular lipids, and degradation via beta-oxidation. It plays an important role in fatty acid metabolism in brain and the acyl-CoAs produced may be utilized exclusively for the synthesis of the brain lipid. FACL6 is expressed predominantly in erythrocyte precursors, in particular in reticulocytes, fetal blood cells derieved from fetal liver, haemopoietic stem cells from cord blood, bone marrow, and brain. Expression is low at earlier stages of erythroid development but is very high in reticulocytes. This protein is involved in myelodysplastic syndrome (MDS) with basophilia, acute myelogenous leukemia (AML) with eosinophilia, and acute eosinophilic leukemia (AEL). It is characterized by a chromosomal translocation t(5,12)(q31,p13) that involves ETV6 and ACSL6.